Framingham, Massachusetts -- Biotechnology company Alzheon has secured $1.3 million in new venture debt investment, according to an SEC regulatory filing.
Alzheon is focused on developing treatments for neurodegenerative disorders such as Alzheimer's disease, memory and aging related conditions.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
Alzheon is still seeking $3.7 million in additional debt investment, according to the filing.
CEO Martin Tolar founded the company in 2013.